03/01/2018 21:05:06

Prothena to Participate in the 36th Annual J.P. Morgan Healthcare Conference

Related content
03 Jan - 
Prothena to Participate in the 36th Annual J.P. Morgan ..
22 Nov - 
Prothena to Participate in the Evercore ISI Biopharma C..
22 Nov - 
Prothena to Participate in the Evercore ISI Biopharma C..

DUBLIN, Ireland, Jan. 3, 2018 - Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company focused on the discovery, development and commercialization of novel therapies in the neuroscience and orphan categories, today announced that members of its senior management team will present and participate in the 36th Annual J.P. Morgan Healthcare Conference on January 10th at 8:30 AM PT in San Francisco, CA. 

A live webcast of the company presentation can be accessed through the Investors section of the Company's website at www.prothena.com. Following the live presentation, a replay of the webcast will be available on the Company's website for at least 90 days following the presentation date.

About Prothena

Prothena Corporation plc is a global, late-stage clinical biotechnology company establishing fully integrated research, development and commercial capabilities and focused on advancing new therapies in the neuroscience and orphan categories. Fueled by its deep scientific understanding built over decades of research in protein misfolding, Prothena seeks to fundamentally change the course of grave or currently untreatable diseases associated with this biology. Prothena's pipeline of antibody therapeutic candidates targets a number of indications including AL amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002/RG7935) and ATTR amyloidosis (PRX004). The Company continues discovery of additional novel therapeutic candidates where its deep scientific understanding of disease pathology can be leveraged. For more information, please visit the Company's website at www.prothena.com.

Media & Investor Contact:

Ellen Rose, Head of Communications

650-922-2405, ellen.rose@prothena.com


This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Prothena Corporation plc via Globenewswire

Post comment

Related debate

  • 1 week
  • 1 month
  • 1 Year
Ingen indlæg

Man Group PLC : Form 8.3 - [UBM plc] - Amendment

22/01/2018 14:52:32
Amendment to cash-settled derivatives positions and transactions, sections 2(a) and 3(b). FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser: ..

Boussard & Gavaudan Investment Management LLP : Form 8.3 - UBM Plc

22/01/2018 13:22:35
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a)  Identity of the person whose positions/dealings are being disclosed: Boussard & Gavaudan Investment Manage..

Dimensional Fund Advisors Ltd. : Form 8.3 - Tesco Plc - Ordinary shares

22/01/2018 10:54:08
FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the "Code") 1.         KEY INFORMATION (a) Full name of discloser:   Dimensional Fund Advisors Ltd. ("Dimensional"), in its capacity ..

Most read news

  • 24 hours
  • 48 hours
  • 1 week
1
PacketFabric Announces Scalable Connectivity to Multiple Cloud Service Providers
2
Post-stabilisation Pbb € 500mn senior 2022
3
West’s Unified Communications Services Attains Cisco Powered Cisco Spark Service Provider Designation
4
Portola Pharmaceuticals Announces Acceptance of Late-Breaker Abstract Highlighting New Data for Andexanet Alfa at ACC.18
5
Southern Missouri Bancorp Reports Preliminary Results for Second Quarter of Fiscal 2018; Dividend of $0.11 Per Common Share Declared; Conference Call to Discuss Results Scheduled for Tuesday, January 23 at 3:30 P.m. Central Time

Related stock quotes

Buy and sell signals

  • Trend
  • Moneymachine

Copyright Euroinvestor A/S 2018   Disclaimer and Terms of Use
Quote information is delivered by Morningstar.
Data is delayed 15-20 minutes according to the distribution agreements set by the different exchanges.
 
23 January 2018 09:44:31
(UTC+00:00) Dublin, Edinburgh, Lisbon, London
Version: LiveBranchBuild_20180122.2 - EUROWEB4 - 2018-01-23 10:44:31 - 2018-01-23 09:44:31 - 1000 - Website: OKAY